Drug intelligence / Profile preview

firzacorvir

Development stage: Discontinued
Lead developer: Assembly Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**Firzacorvir** (also known as ABI-H2158) is a small molecule cyclic sulfamide **HBV core protein inhibitor** developed by Assembly Biosciences for the treatment of **chronic hepatitis B**. It modulates HBV core protein allosterically, disrupting viral capsid assembly and genome packaging, with potent pan-genotypic anti-HBV activity (EC50 <1 μM). Development reached **Phase 2** trials but was **discontinued** due to hepatotoxicity concerns.

Other names: ABI-H-2158ABI-H2158ABI-H 21582158

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on firzacorvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on firzacorvir.

Explore the full profile